Core Insights - SCYNEXIS, Inc. reported significant achievements that position the company for growth, including positive data for its second-generation drug candidate SCY-247 and a resolution of a disagreement with GSK resulting in a one-time payment of $24.8 million [2][3][5] Financial Performance - For Q3 2025, SCYNEXIS reported revenue of $0.3 million, a decrease from $0.7 million in Q3 2024, primarily from license agreement revenue associated with GSK [8] - Research and development expenses decreased to $5.5 million in Q3 2025 from $8.1 million in Q3 2024, a reduction of 33% driven by various cost decreases [9] - Selling, general and administrative expenses increased to $3.3 million in Q3 2025 from $2.9 million in Q3 2024, an increase of 13% primarily due to higher professional fees [10] - The net loss for Q3 2025 was $8.6 million, or $(0.17) per share, compared to a net loss of $2.8 million, or $(0.06) per share in Q3 2024 [12][20] Cash Position - As of September 30, 2025, SCYNEXIS had cash, cash equivalents, and investments totaling $37.9 million, down from $75.1 million at the end of 2024 [13] - The company expects to receive a one-time payment of $24.8 million from GSK in Q4 2025, resulting in a cash runway of more than two years [5][13] Drug Development Updates - SCY-247, the second-generation triterpenoid antifungal, showed positive results in a Phase 1 SAD/MAD study, demonstrating good tolerability and achieving target exposures at lower doses than the first-generation drug [6][14] - The company plans to initiate a Phase 1 study with the intravenous formulation of SCY-247 in Q1 2026 and a Phase 2 study for invasive candidiasis, with proof-of-concept data expected in 2026 [6][7] Partnership with GSK - SCYNEXIS resolved a disagreement with GSK, leading to a one-time payment of $24.8 million and the termination of the Phase 3 MARIO study on invasive candidiasis [3][5] - GSK is committed to relaunching BREXAFEMME® (ibrexafungerp), with SCYNEXIS set to receive up to approximately $146 million in annual net sales milestones and low to mid-single-digit royalties [5][15]

Core Insights - SCYNEXIS, Inc. is set to present data on its second-generation antifungal drug candidate SCY-247 at the TIMM-12 Congress, highlighting its potential against drug-resistant Candida infections, particularly C. auris [1][2] Company Overview - SCYNEXIS, Inc. is a biotechnology company focused on developing innovative medicines to combat difficult-to-treat infections that are increasingly drug-resistant [7] - The company has developed a proprietary antifungal platform called "fungerps," with its first product, Ibrexafungerp, already approved for certain indications [8] Upcoming Presentations - The company will have six presentations at TIMM-12, showcasing SCY-247's efficacy against resistant Candida infections [2] - Key presentations include: - In vitro activity against C. auris, including strains with echinocandin-resistance mutations [3] - Uniform activity against various Candida species with no cross-resistance to echinocandins [5] - Efficacy in a murine model of C. auris infection, demonstrating significant reductions in fungal burden [6] Clinical Trials - SCYNEXIS anticipates reporting results from its Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) trial for SCY-247 in Q3 2025, marking a significant step in the drug's development [4][9]

Core Viewpoint - SCYNEXIS, Inc. reported its financial results for the year ended December 31, 2024, highlighting significant developments in its antifungal drug pipeline and a notable decrease in both revenue and expenses compared to the previous year [1][5][11]. Financial Performance - Total revenue for 2024 was $3.7 million, a decrease from $130.1 million in 2023, primarily due to the recognition of license agreement revenue associated with GSK [5][11]. - Research and development expenses decreased to $26.4 million in 2024 from $30.9 million in 2023, a reduction of $4.5 million or 14.6% [6]. - Selling, general and administrative expenses also saw a decrease to $14.5 million in 2024 from $20.9 million in 2023, a decline of $6.5 million or 30.9% [9]. - The net loss for 2024 was $21.3 million, translating to a basic loss per share of $0.44, compared to a net income of $67.0 million and earnings per share of $1.40 in 2023 [11][18]. Cash Position - As of December 31, 2024, the company had cash, cash equivalents, and investments totaling $75.1 million, down from $98.0 million at the end of 2023, providing a cash runway into Q3 2026 [12][18]. Drug Development Updates - The company initiated a Phase 1 trial for its second-generation antifungal SCY-247 in December 2024, with results expected in Q3 2025 [2][7]. - SCYNEXIS is making progress towards restarting the Phase 3 MARIO trial for invasive candidiasis, pending the FDA's lifting of the clinical hold anticipated in Q2 2025 [2][6][7]. - The company received a $10 million milestone payment from GSK in 2024, linked to the delivery of final study reports from completed studies [7]. Antifungal Platform - SCYNEXIS is developing a proprietary antifungal platform known as "fungerps," with Ibrexafungerp being the first approved agent for vulvovaginal candidiasis and in late-stage development for invasive candidiasis [13][14]. - SCY-247 is positioned as a next-generation fungicide targeting multi-drug-resistant fungal infections, including Candida auris [13].